Gastroenterology
Volume 139, Issue 2 , Pages 393-408.e2, August 2010

Hereditary Hemochromatosis: Pathogenesis, Diagnosis, and Treatment

  • Antonello Pietrangelo

      Affiliations

    • Corresponding Author InformationReprint requests Address requests for reprints to: Antonello Pietrangelo, MD, PhD, 2nd Division of Medicine and Center for Hemochromatosis, University Hospital of Modena, Via del Pozzo 71, 41100 Modena, Italy

2nd Division of Internal Medicine and Centre for Hemochromatosis, University Hospital of Modena, Modena, Italy

Received 1 April 2010; accepted 3 June 2010. published online 14 June 2010.

John P. Lynch and David C. Metz, Section Editors

In the late 1800s, hemochromatosis was considered an odd autoptic finding. More than a century later, it was finally recognized as a hereditary, multi-organ disorder associated with a polymorphism that is common among white people: a 845G→A change in HFE that results in C282Y in the gene product. Hemochromatosis is now a well-defined syndrome characterized by normal iron-driven erythropoiesis and the toxic accumulation of iron in parenchymal cells of liver, heart, and endocrine glands. It can be caused by mutations that affect any of the proteins that limit the entry of iron into the blood. In mice, deletion of the iron hormone hepcidin and any of 8 genes that regulate its biology, including Hfe, transferrin receptor 2 (Tfr2), and hemojuvelin (Hjv) (which all sense the accumulation of iron that hepcidin corrects) or ferroportin (Fpn) (the cellular iron exporter down-regulated by hepcidin), cause iron overload but not organ disease. In humans, loss of TfR2, HJV, and hepcidin itself or FPN mutations result in full-blown hemochromatosis. Unlike these rare instances, in white people, homozygotes for C282Y polymorphism in HFE are numerous, but they are only predisposed to hemochromatosis; complete organ disease develops in a minority, when these individuals abuse alcohol or from other unidentified modifying factors. HFE gene testing can be used to diagnose hemochromatosis, but analyses of liver histology and clinical features are still required to identify patients with rare, non-HFE forms of the disease. The role of hepcidin in the pathogenesis of hemochromatosis reveals its similarities to endocrine diseases such as diabetes and indicates new approaches to diagnosis and management of this common disorder in iron metabolism.

Keywords: Iron Metabolism, Hereditary Disorders, Micronutrients, Hepcidin, HFE

Abbreviations used in this paper: BMP, bone morphogenic protein, FPN, ferroportin, HAMP, hepcidin gene, HJV, hemojuvelin, RGM, repulsive guidance molecule, TfR, transferrin receptor, TS, transferrin saturation

 

 Conflicts of interest The author discloses no conflicts.

 Funding Supported by the PRIN 2008 grant from the Italian National Research Council.

PII: S0016-5085(10)00872-3

doi:10.1053/j.gastro.2010.06.013

Gastroenterology
Volume 139, Issue 2 , Pages 393-408.e2, August 2010